Steven Kane, MD
Ophthalmology · Venice, FLNPI 1467712224
Payments from drug & device makers
Across 205 payments — averaging $305.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bausch & Lomb Americas Inc.$40K
- Biotissue Holdings Inc.$16K
- Rxsight Inc$4K
- Sun Pharmaceutical Industries Inc.$327
- Alcon$304
- AbbVie$295
- plus $1K from 17 others
What the payments were for
- Consulting fees$39,65463%
- Speaking & faculty fees$3,9266%
- Travel & lodging$13,80522%
- Food & beverage$5,2428%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bausch & Lomb Americas Inc. | 71 | $39,944 |
| Biotissue Holdings Inc. | 28 | $16,448 |
| Rxsight Inc | 10 | $4,245 |
| Sun Pharmaceutical Industries Inc. | 18 | $327 |
| Alcon | 16 | $304 |
| AbbVie(2 entities) | 10 | $295 |
| Johnson & Johnson Surgical Vision, Inc. | 9 | $179 |
| Kala Pharmaceuticals, Inc. | 7 | $131 |
| Ocular Therapeutix, Inc. | 6 | $106 |
| Novartis | 5 | $85 |
| Rayner Intraocular Lenses Limited | 3 | $83 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 4 | $78 |
| Harrow Eye, LLC | 3 | $76 |
| Sight Sciences, Inc. | 3 | $60 |
| Dompe US, Inc. | 2 | $60 |
| Glaukos Corporation | 2 | $49 |
| Oyster Point Pharma, Inc. | 2 | $47 |
| Tarsus Pharmaceuticals, Inc. | 1 | $30 |
| Thea Pharma Inc. | 1 | $21 |
| Alimera Sciences, Inc. | 1 | $17 |
| Shire North American Group Inc | 1 | $16 |
| NEW World Medical,inc. | 1 | $14 |
| Coopervision Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- STELLARIS ELITE$38,757
- enVista MX60 IOL$38,757
- Trulign IOL$38,757
- Crystalens Accommodating IOL (AT-52AO)$38,757
- Prokera$15,929
- AmnioGraft$15,929
- AmnioGuard$11,911
- RXSIGHT CONTACT LENS$4,054
- RXSIGHT INJECTOR CARTRIDGE$4,054
- RXSIGHT INJECTOR HANDPIECE$4,054
- RXSIGHT LIGHT DELIVERY DEVICE (LDD)$4,054
- RXSIGHT LIGHT ADJUSTABLE LENS (RXLAL)$2,629
- LIGHT ADJUSTABLE LENS (LAL)$1,425
How this compares
$62,626 in reported general payments places this provider in the 90th percentile of 1,405 ophthalmology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Lotemax SmLoteprednol Etabonate | 242 | $65,296 |
| XiidraLifitegrast | 60 | $56,561 |
| ProlensaBromfenac Sodium | 141 | $48,870 |
| TyrvayaVarenicline Tartrate | 51 | $42,195 |
| MieboPerfluorohexyloctane/Pf | 35 | $27,711 |
| RestasisCyclosporine | 27 | $19,596 |
| VevyeCyclosporine | 13 | $14,258 |
| ValacyclovirValacyclovir Hcl | 137 | $9,421 |
| FlarexFluorometholone Acetate | 56 | $8,222 |
| LumiganBimatoprost | 14 | $6,539 |
| EysuvisLoteprednol Etabonate | 12 | $5,893 |
| Cyclosporine | 16 | $5,180 |
| Prednisolone Acetate | 114 | $4,215 |
| Travoprost | 21 | $3,547 |
| Latanoprost | 189 | $2,055 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bausch & Lomb, A Division Of Bausch Health US, LLCLotemax Sm, Prolensa | $78 | $114,166383 claims |
| Bausch & Lomb Americas Inc.Xiidra, Miebo | $39,944 | $84,27295 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $47 | $42,19551 claims |
| AbbVieRestasis, Lumigan | $295 | $26,13541 claims |
| Harrow Eye, LLCVevye | $76 | $14,25813 claims |
| Kala Pharmaceuticals, Inc.Eysuvis | $131 | $5,89312 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,405 ophthalmology providers in Florida.
Other ophthalmology in Venice
- Patricia StephensonVenice$691K
- Joaquin de RojasVenice$445K
- David EichenbaumSt Petersburg$34.4M
- Robert RadenDelray Beach$7.8M
- Carl DanzigPompano Beach$5.3M
- Bruce SegalDelray Beach$4.7M
- Cathleen McCabeBradenton$4.6M
- Ivan SunerTampa$3.7M
- Sunir JoshiFt Lauderdale$3.7M
- Harold BrooksTallahassee$3.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.